Agarwal Shefali's Form 4 filing
Fate Therapeutics IncFATE · filed Jun 6, 2022
- Accession no.
- 0001209191-22-034536
- Filed
- Jun 6, 2022
- Trade date
- Jun 3, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $18.4K. It was filed 3 days after the trade.
This filing was later replaced by the amendment 0001209191-22-034992 (Jun 8, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Agarwal ShefaliCIK 0001746830 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 | Common Stock | SSaleDisposed | −807 | $22.80F2 | −$18,399.6 | 1,874 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $22.53 to $22.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2.
Referenced by the price of 1 transaction in Table I.